Table 1.
Treatment outcomes of amantadine in children and adolescents, overall and by diagnosis
| Diagnosis | Total | Success | Minimal | Failure | SE D/C | 
|---|---|---|---|---|---|
| Full study group | 297 | 185 (62.3%) | 61 (20.5%) | 34 (11.4%) | 17 (5.7%) | 
| ADHD | 251 | 162 (64.5%) | 52 (20.7%) | 27 (10.8%) | 10 (4.0%) | 
| ODD/CD | 190 | 114 (60%) | 43 (22.6%) | 19 (10%) | 14 (7.4%) | 
| Depressive disorder | 36 | 24 (66.7%) | 10 (27.8%) | 2 (5.6%) | 0 | 
| Anxiety disorder/OCD | 92 | 62 (67.4%) | 17 (18.5%) | 9 (9.8%) | 4 (4.4%) | 
| Autistic spectrum disorder | 59 | 40 (67.8%) | 12 (20.3%) | 2 (3.4%) | 5 (8.5%) | 
| PTSD | 18 | 10 (55.6%) | 2 (11.1%) | 6 (33.3%) | 0 | 
| Intellectual disability | 43 | 28 (65.1%) | 10 (23.3%) | 4 (9.3%) | 1 (2.3%) | 
ADHD indicates attention deficit/hyperactivity disorder (combined and inattentive); OCD, obsessive-compulsive disorder; ODD/CD, oppositional defiant disorder/conduct disorder; PTSD, posttraumatic stress disorder; SE D/C, side effect discontinuation.